Search - tctmd.com

Displaying 241 - 260 of 375

Sort: Relevancy | Date

Presentation TCT 2016

Chronic Oral Anticoagulants: Limitations, Use Recommendations, and Investigational Agents

Presenter: Paul A. Gurbel, Christopher B. Granger

October 30, 2016

Presentation TCT 2016

Antiplatelet Agents: Limitations, Use Recommendations, and Investigational Agents

Presenter: David J. Moliterno

October 30, 2016

Presentation TCT 2016

Procedural Anticoagulants: Limitations, Use Recommendations and, Investigational Agents

Presenter: Paul A. Gurbel, Harvey D. White

October 30, 2016

Presentation TCT 2016

PCI Pharmacotherapy Considerations in Patients With Complicating Co-morbidities (CKD, Liver Disease, ASA Allergy, Prior Stroke, Thrombocytopenia)

Presenter: Sorin J. Brener, Franz-Josef Neumann, Sunil V. Rao

October 30, 2016

Presentation TCT 2016

Atrial Fibrillation Double vs Triple Therapy Considerations and Ongoing Trials

Presenter: Sorin J. Brener, Franz-Josef Neumann, Pascal Vranckx

October 30, 2016

Presentation TCT 2016

Pharmacotherapy for Hybrid PCI/CABG Cases

Presenter: Sorin J. Brener, Franz-Josef Neumann, Laura Mauri

October 30, 2016

Presentation TCT 2016

Limitations of Pharmacotherapy in Complicated PCI Anatomy (Diffuse CAD, Bifurcations, CAD, Calification, SVG, CTO, etc.)

Presenter: Sorin J. Brener, Franz-Josef Neumann, Usman Baber

October 30, 2016

Presentation TCT 2016

ACS Case Presentation: Where Pharmacotherapy Failed

Presenter: C. Michael Gibson, Daniel I. Simon, Gennaro Giustino

October 30, 2016

Presentation TCT 2016

Limitations of Pharmacotherapy Clinical Trial Design

Presenter: C. Michael Gibson, Daniel I. Simon, Sanjay Kaul

October 30, 2016

Presentation TCT 2016

Unmet Needs and Data Gaps for Pharmacotherapy in Patients With STEMI

Presenter: C. Michael Gibson, Daniel I. Simon, Sunil V. Rao

October 30, 2016

Presentation TCT 2016

Unmet Needs and Data Gaps for Pharmacotherapy in Patients With NSTE-ACS

Presenter: C. Michael Gibson, Daniel I. Simon, Glenn N. Levine

October 30, 2016

Presentation ESC 2016

ANTARCTIC: Assessment of a Normal vs Tailored Dose of Prasugrel After Stenting in 75 yo Patients to Reduce the Composite of Bleeding, Stent Thrombosis and Ischemic Complications

Presenter: Gilles Montalescot

August 28, 2016

Presentation

Impact Of Gender on 2-Year Clinical Outcomes in Patients Treated With 6- or 24-Month DAPT

Presenter: Giuseppe Gargiulo

August 19, 2016

Presentation

Outcomes Among Older Stable Angina Patients Prescribed Beta-Blockers After PCI

Presenter: AA. Motivala

August 17, 2016

Presentation

Antiplatelet Therapy and Outcomes in Patients Undergoing Surgery After Stenting

Presenter: Roberta Rossini

July 18, 2016

Presentation CCVVC 2016

Optimal Duration of DAPT: Update on DAPT Guidelines

Presenter: Roxana Mehran

June 16, 2016

Presentation SOLACI 2016

Adjunctive Pharmacology for Patients with ACS Treated Invasively

Presenter: Eric R. Bates

June 09, 2016

Presentation EuroPCR 2016

Effect of DAPT Termination at 12 Months on Very Late scaffold thrombosis in regular clinical practice: Data of a regional collaboration

Presenter: Robert-Jan van Geuns

May 18, 2016

Presentation

Safety and Use of Anticoagulation After Aortic Valve Replacement With Bioprostheses

Presenter: Haris Riaz

May 11, 2016

Presentation

Proton-Pump Inhibitors (PPIs) Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy

Presenter: Muthia Vaduganathan

March 22, 2016

Advertisement

Chronic Oral Anticoagulants: Limitations, Use Recommendations, and Investigational Agents

Antiplatelet Agents: Limitations, Use Recommendations, and Investigational Agents

Procedural Anticoagulants: Limitations, Use Recommendations and, Investigational Agents

PCI Pharmacotherapy Considerations in Patients With Complicating Co-morbidities (CKD, Liver Disease, ASA Allergy, Prior Stroke, Thrombocytopenia)

Atrial Fibrillation Double vs Triple Therapy Considerations and Ongoing Trials

Pharmacotherapy for Hybrid PCI/CABG Cases

Limitations of Pharmacotherapy in Complicated PCI Anatomy (Diffuse CAD, Bifurcations, CAD, Calification, SVG, CTO, etc.)

ACS Case Presentation: Where Pharmacotherapy Failed

Limitations of Pharmacotherapy Clinical Trial Design

Unmet Needs and Data Gaps for Pharmacotherapy in Patients With STEMI

Unmet Needs and Data Gaps for Pharmacotherapy in Patients With NSTE-ACS

ANTARCTIC: Assessment of a Normal vs Tailored Dose of Prasugrel After Stenting in 75 yo Patients to Reduce the Composite of Bleeding, Stent Thrombosis and Ischemic Complications

Impact Of Gender on 2-Year Clinical Outcomes in Patients Treated With 6- or 24-Month DAPT

Outcomes Among Older Stable Angina Patients Prescribed Beta-Blockers After PCI

Antiplatelet Therapy and Outcomes in Patients Undergoing Surgery After Stenting

Optimal Duration of DAPT: Update on DAPT Guidelines

Adjunctive Pharmacology for Patients with ACS Treated Invasively

Effect of DAPT Termination at 12 Months on Very Late scaffold thrombosis in regular clinical practice: Data of a regional collaboration

Safety and Use of Anticoagulation After Aortic Valve Replacement With Bioprostheses

Proton-Pump Inhibitors (PPIs) Reduce Gastrointestinal Events Regardless of Aspirin Dose in Patients Requiring Dual Antiplatelet Therapy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content